Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Daraxonrasib · Rasonque, RMC-6236

Small molecule · Inhibitor of RAS GTPase (KRAS, NRAS, HRAS) (KRAS) · developed by Revolution Medicines

Approved FDA, Aug 2026
RVMD Developer
4 Registered trials

What is Daraxonrasib?

Daraxonrasib is an orally bioavailable RAS inhibitor that binds cyclophilin A and the active, GTP-bound form of wild-type and mutant KRAS, NRAS and HRAS, forming a tri-complex that blocks downstream RAS signaling. It is being studied in pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer and other advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rasonque, RMC-6236, RMC-0706236
Drug type
Small molecule
Targets
RAS GTPase (KRAS, NRAS, HRAS) (KRAS)
Mechanism
Inhibitor of RAS GTPase (KRAS, NRAS, HRAS) (KRAS)
Pathways
RAS signaling, downstream effector signaling, GTP hydrolysis
Therapy area
Oncology
Developer
Revolution Medicines (RVMD)
Also in trials of
TNGX
FDA status
Approved as Rasonque (August 26, 2026), NDA220910 · FDA label
UNII
B6T47Y2UAP

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07252232 Phase 3 Pancreatic Cancer Recruiting RVMD
NCT06625320 Phase 3 Pancreatic Cancer Active not recruiting RVMD
NCT07397338 Phase 1/2 Advanced Solid Tumors Recruiting RVMD
NCT06922591 Phase 1/2 PDAC Recruiting TNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsColorectal Cancer (CRC)CRCLung CancerMetastatic Solid TumorsMTAP DeletionNon-small Cell Lung Cancer (NSCLC)NSCLCPancreatic CancerPancreatic Cancer MetastaticPancreatic Ductal Adenocarcinoma (PDAC)PDACPDAC - Pancreatic Ductal AdenocarcinomaRAS Mutation

Other drugs acting on KRAS

More from Revolution Medicines

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the RVMD page.

Follow RVMD, the company behind Daraxonrasib

See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RVMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.